MedTrace Logo

Evaluation of the Efficacy of Transcranial Magnetic Stimulation on Resistant Auditory Hallucinations in Schizophrenia

NCT06599372 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-09-19

No results posted yet for this study

Summary

This open naturalistic study aims to evaluate the efficacy of rTMS in routine practice on auditory resistant hallucinations (AHR) of patients with schizophrenia. To this end, two stimulation methods will be offered to patients: the rTMS stimulation method and the cTBS stimulation method.We principally use the AHRS scale to evaluate the effectiveness of rTMS on RAH in patients with schizophrenia. Our main hypothesis is that rTMS used under naturalistic conditions, in addition to antipsychotics, would allow a relative improvement of resistant auditory hallucinations assessed by the AHRS scale between baseline and end of treatment in patients with schizophrenia.

Conditions

  • Schizophrenia
  • Transcranial Magnetic Stimulation
  • Hallucinations, Verbal Auditory

Interventions

OTHER

The rTMS method

The patient receives treatment under naturalistic conditions in routine practice.

OTHER

The cTBS method

The patient receives the treatment under naturalistic conditions in routine practice.

Sponsors & Collaborators

  • Dominique JANUEL

    lead OTHER

Principal Investigators

  • Dominique JANUEL · Clinical research unit, EPS Ville Evrard

  • Noomane BOUAZIZ · Clinical research unit, EPS Ville Evrard

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-11
Primary Completion
2027-07-31
Completion
2027-11-30

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06599372 on ClinicalTrials.gov